Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Myriad Genetics, Inc.

35 indications, side-by-side phase, drug & LoA

$4.33

-0.3 (-6.48%)

D 34Pipeline Score Diagnostics · Commercial
Market Cap
360.79 M
EPS
-4.32
P/E Ratio
-
Value Trade
8.64 M
SEC Financials
Q1 2026

  • Dilution Risk

    15%

  • Revenue

    200.40 M

  • R&D Expenses

    27.10 M

  • Operating CF

    -15.70 M

  • Total Assets

    673.70 M

  • Total Liabilities

    336.30 M

  • Equity

    337.40 M

  • D/E Ratio

    12,345

5.52 %
Week
-23.45 %
1 Month
-11.57 %
3 Month
-44.72 %
6 Month
-86.24 %
5 Year
-17.83 %
All Time
Cash Data
Stable

  • Cash Position

    124.40 M

  • Monthly Burn

    5.23 M

  • Runway

    22.7 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 6, 2026
Overview
Volume
1.19 M
52 Week Range
3.53 - 8.59
% held by Insiders
6.37 %
% held by Institutions
93.61 %
Enterprise Value
447.89 M
Total Shares
93.49 M
Short %
9.67 %
Float Shares
89.75 M
Company Description
HQ: 322 NORTH 2200 WEST, SALT LAKE...
Employees:2,700
https://www.myriad.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D34
Pipeline Score
$238M
Pipeline Value
Valuation Signal
4
Drugs Scored
2.2x
rNPV / MCap
Top 40%
Micro Cap
(rank 544 of 905)
Percentile Rank
Myriad Genetics, Inc. faces pipeline headwinds (34/100), with $636M risk-adjusted pipeline value, led by rucaparib in Ovarian Cancer (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
rucaparib
Small molecule		Ovarian CancerPhase 3NCT0189134446% $265M COMPLETED 1,055 - -Sep 28, 2021 -Jun 12, 2023
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Precise®MRD
oligometastatic clear-cell renal cell carcinoma
Phase 2
2025-09-05
Precise®MRD
oligometastatic clear-cell renal cell carcinoma
Phase 2
2025-09-05
Precise®MRD
oligometastatic clear-cell renal cell carcinoma
Phase 2
2025-09-05
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in MYGN
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
MYGN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MYGN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MYGN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
MYGN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
MYGN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Myriad Genetics, Inc. (MYGN) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How MYGN ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Genetic Mutations #2 of 4 PHASE 1 Melphalan + BCNU + Vitamin B12B + Vitamin C
TNGX ANL KTTA
—0.91 CONTENDER
Genetic Predisposition to Cancer #2 of 2 PHASE 1 Melphalan + BCNU + Vitamin B12B + Vitamin C
AZN
—0.91 CONTENDER
Pancreatic Cancer #45 of 73 PHASE 1 Melphalan + BCNU + Vitamin B12B + Vitamin C
RVMD RCUS AZN
$3.7B 0.91 FOLLOWER
Breast Cancer #50 of 94 PHASE 1 Melphalan + BCNU + Vitamin B12B + Vitamin C
MRK AZN GILD
$10.85B 0.91 FOLLOWER